Literature DB >> 19893042

TRAIL-deficient mice exhibit delayed regression of retinal neovascularization.

Kristin E Hubert1, Michael H Davies, Andrew J Stempel, Thomas S Griffith, Michael R Powers.   

Abstract

While it is well established that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various cell types, the role of TRAIL in regulation of retinal neovascularization (NV) has not been described. Here we determined the role of TRAIL in retinal NV during oxygen-induced retinopathy using TRAIL deficient ((-/-)) mice. TRAIL and its receptor, DR5, were expressed in wild-type retinas at all time points evaluated (postnatal days 12, 17, 21, 24) during oxygen-induced retinopathy and in age-matched room air control animals. Localization of TRAIL(+) cells within the neovascular tufts of hyperoxia- exposed wild-type mice suggested TRAIL plays a role in oxygen-induced retinopathy. Retinal vascular development appeared normal in the TRAIL(-/-) mice, except for a small but significant difference in the capillary-free zone surrounding major arteries. A minimal difference in avascularity was observed at postnatal day 12 in the retinas of TRAIL(-/-) mice after hyperoxia-exposure compared with wild-type mice, suggesting that TRAIL does not play a major role in the vaso-obliterative phase of oxygen-induced retinopathy. However, at the peak of NV, TRAIL(-/-) mice had a significant increase in retinal neovascularization. In addition, when NV naturally regresses in wild-type mice, TRAIL(-/-) mice continued to display significantly high levels of NV. This was attributed to a significant decrease in neovascular tuft cells undergoing apoptosis in TRAIL(-/-) mice. Together, these data strongly suggest that TRAIL plays a role in the control of retinal NV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893042      PMCID: PMC2789602          DOI: 10.2353/ajpath.2009.090099

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification.

Authors:  Eyal Banin; Michael I Dorrell; Edith Aguilar; Matthew R Ritter; Christopher M Aderman; Alexandra C H Smith; Jeffrey Friedlander; Martin Friedlander
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

2.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Authors:  Vera Levina; Adele M Marrangoni; Richard DeMarco; Elieser Gorelik; Anna E Lokshin
Journal:  Exp Cell Res       Date:  2008-01-16       Impact factor: 3.905

3.  Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).

Authors:  Gerard A Lutty; Tailoi Chan-Ling; Dale L Phelps; Anthony P Adamis; Kenneth I Berns; Candy K Chan; Cynthia H Cole; Patricia A D'Amore; Arup Das; Wen-Tao Deng; Velma Dobson; John T Flynn; Martin Friedlander; Anne Fulton; William V Good; Maria B Grant; Ronald Hansen; William W Hauswirth; Robert J Hardy; David R Hinton; Suzanne Hughes; D Scott McLeod; Earl A Palmer; Arnall Patz; John S Penn; Brian J Raisler; Michael X Repka; Magali Saint-Geniez; Lynn C Shaw; David T Shima; Bradley T Smith; Lois E H Smith; Sjakon G Tahija; William Tasman; Michael T Trese
Journal:  Mol Vis       Date:  2006-05-23       Impact factor: 2.367

4.  Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.

Authors:  Eva Baader; Agnieszka Toloczko; Uta Fuchs; Irene Schmid; Christian Beltinger; Harald Ehrhardt; Klaus-Michael Debatin; Irmela Jeremias
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

5.  Altered retinal neovascularization in TNF receptor-deficient mice.

Authors:  Ron C Ilg; Michael H Davies; Michael R Powers
Journal:  Curr Eye Res       Date:  2005-11       Impact factor: 2.424

6.  Microglia and macrophages are increased in response to ischemia-induced retinopathy in the mouse retina.

Authors:  Michael H Davies; Joshua P Eubanks; Michael R Powers
Journal:  Mol Vis       Date:  2006-05-10       Impact factor: 2.367

7.  TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.

Authors:  Salima J Alladina; Jin H Song; Sandra T Davidge; Chunhai Hao; Alexander S Easton
Journal:  J Vasc Res       Date:  2005-06-28       Impact factor: 1.934

8.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

Authors:  Klaus W Wagner; Elizabeth A Punnoose; Thomas Januario; David A Lawrence; Robert M Pitti; Kate Lancaster; Dori Lee; Melissa von Goetz; Sharon Fong Yee; Klara Totpal; Ling Huw; Viswanatham Katta; Guy Cavet; Sarah G Hymowitz; Lukas Amler; Avi Ashkenazi
Journal:  Nat Med       Date:  2007-09-02       Impact factor: 53.440

9.  Death receptor expression and function at the human blood brain barrier.

Authors:  Karolina Wosik; Katarzyna Biernacki; Marie-Pierre Khouzam; Alexandre Prat
Journal:  J Neurol Sci       Date:  2007-03-28       Impact factor: 3.181

Review 10.  TRAIL and cancer therapy.

Authors:  Frank A E Kruyt
Journal:  Cancer Lett       Date:  2008-03-10       Impact factor: 8.679

View more
  11 in total

Review 1.  Endothelial cell apoptosis in angiogenesis and vessel regression.

Authors:  Emma C Watson; Zoe L Grant; Leigh Coultas
Journal:  Cell Mol Life Sci       Date:  2017-06-23       Impact factor: 9.261

Review 2.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.

Authors:  Bharat B Aggarwal; Subash C Gupta; Ji Hye Kim
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

3.  The regulatory roles of apoptosis-inducing factor in the formation and regression processes of ocular neovascularization.

Authors:  Toshio Hisatomi; Shintaro Nakao; Yusuke Murakami; Kousuke Noda; Toru Nakazawa; Shoji Notomi; Edward Connolly; Haicheng She; Lama Almulki; Yasuhiro Ito; Demetrios G Vavvas; Tatsuro Ishibashi; Joan W Miller
Journal:  Am J Pathol       Date:  2012-05-19       Impact factor: 4.307

4.  The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and reduces pathological neovascularization associated with ischemic retinopathy.

Authors:  Adeel Hasan; Nataliya Pokeza; Lynn Shaw; Hyun-Seung Lee; Douglas Lazzaro; Hemabindu Chintala; Daniel Rosenbaum; Maria B Grant; Brahim Chaqour
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

Review 5.  Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking.

Authors:  Luyan Liu; Yi Wu; Kaiyan Ye; Meichun Cai; Guanglei Zhuang; Jieyi Wang
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

Review 6.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

Review 7.  TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.

Authors:  Paolo Perri; Giorgio Zauli; Arianna Gonelli; Daniela Milani; Claudio Celeghini; Giuseppe Lamberti; Paola Secchiero
Journal:  Biomed Res Int       Date:  2015-03-05       Impact factor: 3.411

Review 8.  Contribution of cell death signaling to blood vessel formation.

Authors:  Nathalie Tisch; Carmen Ruiz de Almodóvar
Journal:  Cell Mol Life Sci       Date:  2021-03-30       Impact factor: 9.261

Review 9.  Graft microvascular disease in solid organ transplantation.

Authors:  Xinguo Jiang; Yon K Sung; Wen Tian; Jin Qian; Gregg L Semenza; Mark R Nicolls
Journal:  J Mol Med (Berl)       Date:  2014-06-01       Impact factor: 4.599

Review 10.  Repositioning the Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) on the TRAIL to the Development of Diabetes Mellitus: An Update of Experimental and Clinical Evidence.

Authors:  Chrysi Koliaki; Nicholas Katsilambros
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.